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ABSTRACT
Inhibitor of differentiation 2 (Id2) is a natural inhibitor
of the basic helix–loop–helix transcription factors.
Although Id2 is well known to prevent differentiation
and promote cell-cycle progression and tumorigen-
esis, the molecular events that regulate Id2 activity
remain to be investigated. Here, we identified
that Four-and-a-half LIM-only protein 2 (FHL2) is a
novel functional repressor of Id2. Moreover, we
demonstrated that FHL2 can directly interact with
all members of the Id family (Id1–4) via an N-terminal
loop–helix structure conserved in Id proteins. FHL2
antagonizes the inhibitory effect of Id proteins on
basic helix–loop–helix protein E47-mediated tran-
scription, which was abrogated by the deletion
mutation of Ids that disrupted their interaction with
FHL2. We also showed a competitive nature
between FHL2 and E47 for binding Id2, whereby
FHL2 prevents the formation of the Id2–E47 hetero-
dimer, thus releasing E47 to DNA and restoring
its transcriptional activity. FHL2 expression was
remarkably up-regulated during retinoic acid-
induced differentiation of neuroblastoma cells,
during which the expression of Id2 was opposite
to that. Ectopic FHL2 expression in neuroblastoma
cells markedly reduces the transcriptional and
cell-cycle promoting functions of Id2. Altogether,
these results indicate that FHL2 is an important
repressor of the oncogenic activity of Id2 in neuro-
blastoma cells.
INTRODUCTION
Inhibitor of diﬀerentiation (Id) proteins are key regulators
in a wide range of developmental and cellular processes
by regulating transcriptional networks (1,2). Id proteins
themselves do not bind to DNA because of lack of a
DNA-binding domain, but they preferentially bind to ubi-
quitously expressed basic helix–loop–helix (bHLH) factor
E proteins (E47, E2–2 and HEB) and sequester them from
tissue-speciﬁc bHLH proteins (3,4). The E transcription
factor engaged by Id proteins is no longer able to bind
to an E-box DNA target sequence and activate transcrip-
tion. The factors aﬀecting the balance of the Id/bHLH
activity are expected to be critical to the whole cellular
equilibrium (5–7).
So far, four individual Id genes, Id1–4, have been iden-
tiﬁed in mammals. All members of the Id protein family
share a similar structure consisting of a highly conserved
HLH domain. Among them, Id2 has been extensively
studied in several cell types and in animal models
and found to be not only an inhibitor of diﬀerentia-
tion but also a positive regulator of cell proliferation
and oncogenesis (5,6,8). Aberrant elevation of Id2,
typically activated by oncoproteins such as Myc and
Ews–Fli1, was frequently observed in tumors from the
central and peripheral nervous system (9–12). The aber-
rant accumulation of Id2 contributes to uncontrolled pro-
liferation and neoangiogenesis, two hallmarks of neural
cancers (13).
Similar to the regulation of other transcription factors,
Id protein activity has been previously reported to be
controlled by additional Id partners that are unrelated
to transcription factors (8). These studies have largely
focused on Id2. Among the partners is the retinoblastoma
tumor suppressor protein Rb. Rb binds to and antago-
nizes Id2 from binding to transcription factors, thus
releasing bHLH protein-mediated transcription
(10,14,15). Recently, cytoplasmic proteins such as
enigma homolog (ENH), polycystin-2 (PC2) and inter-
feron-induced protein p204 were reported to bind to Id2
and sequestrate it into cytoplasm, thus preventing
the access of Id2 to its nuclear partners (16–18). Loss of
the cytoplasmic adaptor ENH was suggested to boost
Id2 activity in aggressive neuroblastomas (16). In view
of the oncogenic activity of Id2, proteins that prevent
Id2 from binding to bHLH factors may be potential
tumor suppressors.
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best-studied member of the FHL family, which is
expressed in several human adult tissues, including
the brain (19,20). FHL2 has no DNA-binding activity
but can regulate multiple cell signaling pathways by inter-
acting with various transcription factors known to be
involved in development and tumorigenesis (19). The
function of FHL2 in cancer is particularly intriguing,
because it may act as an oncoprotein or as a tumor sup-
pressor in a tissue-dependent fashion (21). The dual nature
of FHL2 is reﬂected by the ﬁnding that it functions
as activator or repressor of its interacting transcription
factors depending on the cell type. So far, the FHL2 func-
tion in neuroblastoma cells is still unclear.
Mediation of the interaction of almost all recognized
partners with Id2 is considered to be through its HLH
domain. An exception is APC/C
CDH1, which interacts
with Id2 through the D-box domain of Id2 and mediates
ubiquitin-dependent proteasomal degradation of Id2 (22).
We supposed that Id2/bHLH activity may also be regu-
lated by proteins interacting with Id2 via the non-HLH
region. We used the HLH-deleted and D-box-mutated
human Id2 as bait protein in a yeast two-hybrid system
to identify novel Id2 interactors. FHL2 was identiﬁed to
physically interact with Id proteins through an N-terminal
conservation region. FHL2, whose expression increased
during retinoic acid (RA)-induced diﬀerentiation of
neuroblastoma cells, competitively prevented Ids from
binding to E47 and thus largely restored E47-mediated
transcription. Finally, we proposed an anti-proliferation
function of FHL2 in neural cells by showing that FHL2
can inactivate the transcriptional and cell-cycle-promoting
functions of Id2 in neuroblastoma cells.
MATERIALS AND METHODS
Plasmids and siRNA
The plasmids including pcDNA3–Id2–DBM containing
the complete coding sequence of the full-length human
Id2 with a D-box mutation (22), 5xE-box-Luc reporter
and pcDNA3-E47 were kindly provided by Dr Iavarone
(Columbia University Medical Center, New York).
The Id2–DBM–dHLH fragment, lacking the entire HLH
domain (codons 35–76 aa), was derived from pcDNA3–
Id2–DBM by a sequential PCR scheme as described pre-
viously. The human full-length Id2 cDNA was obtained
from Dr Desprez (California Paciﬁc Medical Center,
San Francisco). The human Id4 cDNA was provided by
Dr Junjie Wu (Weill Medical College, Cornell University,
Ithaca, New York). The full-length Flag-tagged FHL2
and the deletion mutants of FHL2 in pcDNA3 were
donated by Dr Qinong Ye as described previously (23).
Id1 and Id3 were ampliﬁed from a human endometrium
cDNA library. The various deletion mutants of Ids
and E47 were constructed by PCR and were subsequently
subcloned into pcDNA3.1, pGEX-6P1, pBIND or pACT
vectors through appropriate digestion sites.
Oligonucleotides for siRNA were chemically synthe-
sized by Shanghai GeneChem Co. (Shanghai). The
human FHL2-speciﬁc siRNA, 50-AACTGCTTCTGTGA
CTTGTAT-30 (sense strand), was as described previously
(24). The unrelated siRNA sequence (sense strand, 50-AA
GACGAACGTGTCACGTATC-30) was used as a
control.
Yeast two-hybrid screening and mammalian two-hybrid
assays
The HLH-deleted Id2–DBM (Id2–DBM–dHLH) was
inserted in-frame into the Gal4 DNA-binding domain
vector pGBKT7. A human MCF-7 cDNA library, pre-
pared by the use of the BD SMART
TM kit (Clontech)
according to the manufacturer’s instructions, with
some modiﬁcations, was screened according to protocols
recommended by the MATCHMAKER two-hybrid
system 3 kit.
Mammalian two-hybrid assays were performed in cells
as described previously (25).
Cell culture, transfection and colony-forming assay
MCF-7, 293T, SK–N–SH, SH–SY5Y and COS-7 cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium
(Invitrogen, Carlsbad, CA) supplemented with 10–15%
FBS (Hyclone). An amount of 1mM retinoic acid
(Sigma, St. Louis, MO) was used to induce diﬀerentiation
of SK–N–SH and SH–SY5Y cells. DNA transfection
involved use of Superfect reagent (Qiagen, Hilden,
Germany). Transfection with siRNA duplexes involved
use of Lipofectamine 2000 (Invitrogen). For colony-form-
ing assay, transfected cells were selected with G418
(Invitrogen) for 14 days. Colonies were scored in triplicate
cultures at least three times.
GST pull-down assay
GST and GST fusion proteins were prepared as described
previously (26).
35S-labeled proteins were produced
with use of a Promega’s TNT-coupled in vitro transcrip-
tion and translation (IVT) system, with the expression
vectors for E47, FHL2 and its derivatives in pcDNA3.
GST pull-down assay was performed as described (26).
Coimmunoprecipitation (CoIP) and western blot analysis
Cells were cultured in 10-cm dishes and transfected with or
without expression vectors. At 48h after transfection,
cells were harvested and total proteins or nuclear proteins
were extracted. The CoIP and western blot assays were
performed as described previously (26). The rabbit anti-
Flag (Sigma), Myc tag (Abcam, Cambridge, MA),
GAL4DBD (Clontech), Id2 (Santa Cruz Biotechnology
or Abcam), E47 (Santa Cruz), b-actin (Santa Cruz),
FHL2 antibodies (Aviva Systems Biology, Beijing) and
the mouse anti-p57
Kip2 antibody (Santa Cruz) were used
for immunoprecipitation or immunoblotting.
Luciferase assay
The luciferase reporter construct 5xE-box-Luc was
cotransfected with pcDNA3-E47, pcDNA3.1-Id1-4
and/or pcDNA3.1-Id-del and/or pcDNA3.1-FHL2, or
FHL2-siRNA/control-siRNA into cells. pRL-SV40 was
used as an inner control. Forty-two hours later, cells
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measured as described previously (26).
Northern blot and quantitative RT-PCR (qPCR)
Total RNA was extracted with TRIzol reagent
(Invitrogen) and underwent northern blot analysis as pre-
viously described (26). The membranes were probed with
a 612-bp fragment of FHL2, a 402-bp fragment of Id2 and
a 515-bp b-actin fragment labeled with [
32P]dCTP by ran-
dom priming.
For qPCR experiments, cDNA was prepared by use
of Superscript II RNase H
  reverse transcriptase
(Invitrogen) and 1–2mg total RNA. The PCR primer
sets for p57
Kip2, IGF2, H19 and HPRT were as previously
reported (27). Reactions were run on a LightCycler
(Roche).
G1/S checkpoint assay
SK–N–SH or SH–SY5Y cells were seeded in 3.5-cm
culture dishes and transfected with plasmids pcDNA3.1,
pcDNA3.1-Id2, pcDNA3.1-Id2-del and/or pcDNA3.1-
FHL2 or FHL2-siRNA/control-siRNA. An EGFP-
expressing vector was used to identify transfected cells.
After 48h, cells were labeled with 10mM BrdU for 2h.
Immunostaining involved use of anti-BrdU antibody
(Becton Dickinson). The proportion of BrdU and EGFP
double-positive cells to EGFP-positive cells was deter-
mined by use of an Olympus ﬂuorescence microscope.
At least 350 cells from each plate were counted. The
mean and SEM were calculated from three separate
plates of three independent experiments.
Chromatin immunoprecipitation (ChIP) assay
MCF-7 cells at 80% conﬂuence in 10cm tissue culture
plates were transiently cotransfected with 5mg of 5xE-
box-Luc and 5mg of siRNA duplexes by use of
Lipofectamine 2000 reagent. After 48h, ChIP assays
were performed according to the protocol for the ChIP
assay kit (Upstate Biology, NY). Immunoprecipitation
involved E47 antibody or non-speciﬁc IgG. DNA frag-
ment were puriﬁed with use of a QIAquick Spin Kit
(Qiagen). The presence of the target DNA sequences in
both the input and the recovered DNA immunocomplexes
was detected by PCR. The 5xE-box was ampliﬁed with
its ﬂanking sequence used as the primer set. The forward
primer is 50-AGTGCAAGTGCAGGTGCCAG-30 and the
reverse primer is 50-GCTCTCCACGGTTCCATCT-30.
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) involved
use of in vitro-translated (IVT) proteins and/or puriﬁed
proteins from bacteria. AnnealedmE5 E2-box
oligonucleotide (50-GATCCCAGAACACCTGCAGCA
GGATC-30) probe was generated by labeling with T4
polynucleotide kinase and [g-
32P]dATP. Puriﬁed GST-
E47-bHLH (10ng) and/or GST-Id2 (500ng), GST-Id3
(500ng), IVT-FHL2 (1, 3 or 5ml), or IVT-empty vector
(5ml) were used for each 25ml reaction mixture in a bind-
ing buﬀer. Proteins were incubated for 20min at room
temperature prior to the addition of
32P-labeled probes
(1.75pmol). A 100-fold excess of unlabeled wild-type or
E-box mutantmE5 oligonucleotide (50-GATCCCAGA
ACACTTTCAGCAGGATC-30) was used for competi-
tion experiments. An amount of 0.3mg of anti-E47
(Santa Cruz) or non-speciﬁc IgG were used for super-
shift experiments. The sample was run through a 6%
polyacrylamide gel then dried and subjected to
autoradiography.
Statistical analysis
Experimental results were expressed as the mean 
standard error of the mean (SEM). Statistical analysis
involved use of Statview 5.0 software. Paired Student’s
t-test or two-way ANOVA followed by the Student–
Newman–Keuls test were used where applicable to assess
signiﬁcant diﬀerences between groups. P<0.05 was con-
sidered to be statistically signiﬁcant.
RESULTS
Two-hybrid screening identifies FHL2 as an Id2-interacting
factor independent of its HLH domain
To probe the HLH-independent Id2 interactors, we per-
formed yeast two-hybrid screening using the HLH-deleted
and D-box-mutated Id2 (Id2–DBM–dHLH) as a bait in
conjunction with a cDNA library of human breast cancer
MCF-7 cells. This screening yielded 20 validated cDNA
clones corresponding to 19 diﬀerent proteins. Among
them, the cDNA sequence coding for the full-length
FHL2 (279 aa) was isolated from two individual clones.
Quantiﬁcation of b-galactosidase activity further showed a
speciﬁc interaction between FHL2 and Id2–DBM–dHLH
but not between either factor and the pairwise control
containing only the Gal4 activation domain (AD) or
only the Gal4 DNA-binding domain (DBD) (Figure 1A,
right panel).
To extend these observations from yeast, functional
interaction between FHL2 and Id2 was assessed in 293T
and SH–SY5Y cells by fusing the full-length coding
sequence of FHL2 gene with the GAL4–DBD and
fusing Id2–DBM or Id2–DBM–dHLH with the VP16
AD. As shown in Figure 1B, the chimeric GAL4–DBD–
FHL2 protein only weakly activated the GAL4-dependent
reporter gene, by approximately three- to four-fold in
these cells, which is consistent with previous reports
(28,29). The luciferase activity was signiﬁcantly enhanced
by cotransfection of GAL4–DBD–FHL2 with the
VP16–Id2–DBM or VP16–Id2–DBM–dHLH vector in a
dose-dependent manner (Figure 1B).
Physical interaction between FHL2 and Id2 in vitro and
in vivo
To validate the speciﬁcity of the binding between FHL2
and Id2, we used GST fusion proteins and in vitro-trans-
lated proteins in pulldown assays. GST–Id2 eﬃciently
bound to the in vitro-translated
35S-labeled full-length
FHL2 (Figure 2A). Given the low homology among
the regions outside the HLH domain in Id proteins (30),
3998 Nucleic Acids Research, 2009, Vol. 37,No. 12we investigated the possibility of three other Id members
(Id1, Id3 and Id4) binding to FHL2 in this assay. As
shown in Figure 2A, GST–Id1, GST–Id3 and GST–Id4
bound to the full-length FHL2 as well. The interaction
of FHL2 with all Id proteins is not equivalent in this
assay, as demonstrated in Figure 2A; the retention of
FHL2 by GST–Id3 is substantially greater than that of
the others, given the apparent lower level of this GST
fusion protein. GST–Id2 and GST–Id4 carrying a deletion
of the HLH domain (Id2–dHLH, Id4–dHLH) bound to
FHL2 (Figure 2B), which indicates that the HLH domain
is not required for FHL2-Id interaction.
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4000 Nucleic Acids Research, 2009, Vol. 37,No. 12To determine which region of Ids was responsible
for mediating the interaction with FHL2, the N- and
C-terminal deletion mutants of Id3 (Id3-N and Id3-C)
were tested for their ability to interact with FHL2 by
GST-pulldown assay. The full-length FHL2 was pulled
down by GST–Id3-N but not by GST–Id3-C and GST
alone (Figure 2C). Next, we further showed that the full-
length FHL2 could be pulled downed by the Id2 (1–28 aa)
and Id3 (1–32 aa) mutants (Figure 2C), which suggests
that the N-terminal region of Ids is suﬃcient for FHL2
interaction. We noted a relatively conserved region within
the N termini of Ids (Figure 2D, left panel) that formed a
conserved small loop–helix structure (Figure 2D, middle
panel), so we generated mutant Id proteins (Id1–4) with
this conserved region deleted (Id1-del to Id4-del), and then
performed pulldown assays. Surprisingly, FHL2 could no
longer be pulled down by any of these Id mutants; how-
ever, the bHLH transcriptional factor E47 could be pulled
down by Id2-del (Figure 2D, right panel). These results
indicated that the residues in the N-terminal region of Ids
are indispensable for FHL2 binding. We postulated
that the deletion of residues in the N-terminal region of
Ids may cause a gross conformational change of Ids that
disrupts the binding of FHL2 but not E47.
To more thoroughly characterize the FHL2–Id interac-
tion, we analyzed a series of
35S-labeled FHL2 domain
deletions for interaction with GST–Id2. As shown in
Figure 2E, the full-length FHL2, FHL2C1, FHL2N1
and FHL2N2, but not FHL2C2 and FHL2N3, were
pulled down by GST–Id2, which demonstrates that
both the second and the third LIM domain in FHL2 are
required for the FHL2–Id2 interaction.
To conﬁrm that FHL2 can interact with Id2 in cells,
we transiently transfected COS-7 cells with Flag-FHL2,
Myc-Id2, or a combination of Flag-FHL2 and Myc-Id2.
Cell lysates were ﬁrst precipitated with a Flag anti-
body, then underwent immunoblotting analysis with an
anti-Myc tag or Id2 antibody. An intense band corre-
sponding to Myc-Id2 was detected only in immunopreci-
pitates containing Flag-FHL2 (Figure 2F). The presence
of Id2 in the FHL2-containing immune complexes is spe-
ciﬁc, because an irrelevant GAL4–DBD antibody failed to
immunoprecipitate Id2. A reciprocal coimmunoprecipita-
tion experiment with use of an anti-Myc antibody also
revealed the presence of Flag-FHL2 in the immune com-
plexes containing Myc-Id2 (Figure 2F). Next, we cotrans-
fected Flag-FHL2 and Myc-Id2-del or Myc-Id2-dHLH
into COS-7 cells for CoIP assays. As demonstrated in
Figure 2G, Flag-FHL2/Myc-Id2–dHLH but not Flag-
FHL2/Myc-Id2-del could be reciprocally coimmunopreci-
pitated by use of anti-Flag and/or anti-Myc antibodies.
These results conﬁrmed that the N-terminal loop–helix
structure in Id2 but not the HLH domain is required for
the FHL2–Id2 interaction in the cell system.
FHL2 antagonizes the inhibition of E-box-mediated
transcription by Ids, but not by Id-dels
To explore the possible functional signiﬁcance of the
observed FHL2-Id2 interaction, we performed luciferase
reporter assays with ﬁve multimerized E-boxes driving the
expression of luciferase (5xE-box-Luc). Transfection of
MCF-7 cells with reporter alone or reporter plus FHL2
expression vector revealed background luciferase activity
(Figure 3A, lane 1 and 2). Cotransfection of E-box-Luc
plus E47 signiﬁcantly activated the system in cells (lane 3).
Given that E47/Id2 heterodimers lose the ability to bind to
the E-box, Id2 cotransfection resulted in a signiﬁcant
repression of the E47-activated luciferase activity (lane
5); however, this repression was markedly antagonized
by FHL2 in a dose-dependent manner (lanes 6–8).
FHL2 slightly increased E47 activation of the reporter
(lane 4), which might be due to FHL2 inhibition of the
endogenous Id activities. Similar results were obtained in
293T and SH-SY5Y cells (Figure 3B and C), which
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Nucleic Acids Research, 2009,Vol.37, No. 12 4001suggests that the inhibitory eﬀect of FHL2 on Id2 activity
in this assay is independent of other tissue-speciﬁc cofac-
tors. To further conﬁrm whether this repression was
mediated by the direct interaction of FHL2 and Id2, we
used the Id2-del expression vector, a 9-aa deleted (from 15
to 23 aa) Id2 mutant that cannot interact with FHL2
in vitro and in vivo, as shown in Figure 2D and G, for
luciferase assays. As expected, Id2-del also signiﬁcantly
inhibited E47-mediated reporter activity as did the wild-
type Id2 (Figure 3D, lane 3); however, unlike Id2 repres-
sion, Id2-del repression was not antagonized by FHL2.
Furthermore, we also observed that FHL2 signiﬁcantly
overcame the inhibition of E47-mediated transcription
by Id1, Id3 and Id4 in MCF-7 cells, but this inhibitory
eﬀect was abrogated in Id1-del, Id3-del and Id4-del
mutants (Figure 3E). Taken together, these data strongly
indicate that FHL2 can potently repress Id activities by
directly associating with them, thus restoring the tran-
scription programme driven by E47. To further address
this, we cotransfected 5xE-box-Luc and FHL2-speciﬁc
siRNA into MCF-7 cells for luciferase assays. As shown
in Figure 3F, knock down of the endogenous FHL2
expression led to a commensurate reduction in endogen-
ous E47 activity.
FHL2 antagonizes the binding of Id2 to E47, thus
releasing E47 to its cognate DNA
To explore the molecular mechanism by which FHL2
represses Id activities, we analyzed the interactions
among E47, Id2 and FHL2 proteins present in the nucleus
by performing immunoprecipitation assays with MCF-7
cells cotransfected with E47, Myc-Id2 and/or Flag-
FHL2. Id2 present in both Flag and E47 antibody
immunoprecipitates (Figure 4A, panels V and VIII) and
reciprocal experiment results demonstrated E47 and
FHL2 detected in Myc antibody immunoprecipitates
(panels I and II). These results further conﬁrmed the inter-
action of Id2 with FHL2 or E47. However, neither E47 nor
FHL2 was detected in their mutual immunoprecipitates
(panels IV and VII), which indicates that FHL2 and E47
do not interact and coexist in an Myc–Id2 protein complex
in vivo. The lack of evidence of an FHL2–E47 interaction is
consistent with another report (31). More importantly,
CoIP results showed that the Id2–E47 recognition was
markedly blunted in the presence of ectopic FHL2
(panels I and VIII). These results suggest a competitive
nature between FHL2 and E47 for binding Id2, whereby
FHL2 prevents the formation of an Id2–E47 heterodimer.
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Figure 4. FHL2 competitively blunts the binding of Id2 to E47 and releases E47 to its cognate DNA. (A) FHL2 blunts the E47–Id2 association in
MCF-7 cells. Myc-tagged Id2, E47 and/or Flag-tagged FHL2 were transiently cotransfected into MCF-7 cells. After 48h transfection, cells were
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Nucleic Acids Research, 2009,Vol.37, No. 12 4003On the basis of these results, we further determined
whether the FHL2-Id2 association would release E47 to
its cognate DNA sequence by performing EMSA with
[g-
32P]-labeledmE5, which contains an E-box sequence, a
probe that was previously used as a consensus sequence
for E47 homodimer binding in vitro (32). We ﬁrst identi-
ﬁed the speciﬁc band formed by the E47 andmE5 probe.
As shown in Figure 4B, puriﬁed GST did not bind to
the E5 probe (lane 1). A shifted band representing an
E47–E47 homodimer complex bound to DNA was
observed in the presence of GST–E47 (459–651 aa) (lane
2), which was conﬁrmed by adding a non-labeled mE5, a
mutant probe, or E47-speciﬁc or non-speciﬁc antibodies
(lanes 3–6). The speciﬁc E47-DNA band was not aﬀected
by adding either an IVT-empty vector or IVT-FHL2
proteins (Figure 4C, lanes 2 and 3). As expected, the
E47-DNA band was substantially attenuated when puri-
ﬁed GST-Id2 was added to the reaction system
(Figure 4C, lane 4). This attenuation was not aﬀected by
adding IVT-empty vector proteins (Figure 4C, lane 5) but
was reversed by adding IVT-FHL2 in a dose-dependent
manner (Figure 4C, lanes 6–8). Similar results were
observed with Id3 (Figure 4D). These in vitro data indi-
cated that FHL2 possesses the ability to antagonize the
binding of E47 and Id proteins, thereby releasing E47 to
its target DNA. To further conﬁrm this in-cell system, we
performed ChIP assays after cotransfecting 5xE-box-Luc
and FHL2-speciﬁc siRNA into MCF-7 cells. As shown in
Figure 4E, knockdown of the endogenous FHL2 expres-
sion in MCF-7 cells caused a signiﬁcant reduction of the
endogenous E47 binding to the exogenous DNA target.
FHL2 is greatly induced during differentiation of
neuroblastoma cells, and ectopic FHL2 overcomes
Id2-promoted cell-cycle progression
The ﬁndings in the previous sections prompted us to
investigate whether FHL2 is involved in the biological
processes regulated by the Id2–E47 transcriptome. To do
so, we used human neuroblastoma SK–N–SH and SH–
SY5Y cells, in which the function of the Id2–E47 tran-
scriptome in cell proliferation and diﬀerentiation has
been well studied (10,11,33,34). In addition, human neu-
roblastoma cells are frequently used as in vitro models to
recapitulate diﬀerentiation of the nervous system (35,36).
We tested the dynamic expression of FHL2 during retinoic
acid (RA)-induced diﬀerentiation of these cells. As shown
in Figure 5A, FHL2 expression was very weak and even
negligible in both SK–N–SH and SH–SY5Y cells.
However, treatment with RA (1mM) induced a progres-
sive and remarkable elevation of both FHL2 mRNA and
protein levels. In accordance with previous reports (16,37),
RA administration led to a marked inhibition of Id2
SH-SY5Y SK-N-SH
FHL2
Id2
β-actin
RA (1µM)      0 6 24 48 0 6 24 48  (h)
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Id2
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Western blot
A
B
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FHL2
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Figure 5. The reverse expression and functional interaction of FHL2 and Id2 was induced by retinoic acid (RA) in human neuroblastoma cells. (A)
Northern and western blot analyses of FHL2 and Id2 gene expression in SH–SY5Y and SK–N–SH cells treated with RA (1mM) for the indicated
times. b-actin is used as a loading control. (B) SH–SY5Y cells were treated with RA (1mM) for the indicated times, lysed and underwent CoIP
experiments with the indicated antibodies.
4004 Nucleic Acids Research, 2009, Vol. 37,No. 12gene expression. In RA-untreated SH–SY5Y cells, the
endogenous interaction of FHL2 and Id2 could not be
detected by CoIP assays but could be detected in SH–
SY5Y cells with 6h RA treatment (Figure 5B). The oppo-
site expression style and interaction of FHL2 and Id2
during cell diﬀerentiation induced by RA suggested an
antagonistic role of FHL2 for Id2 activity.
A prominent function of Id2 in neuroblastoma cells is
to encourage cell proliferation by promoting the transition
from the G1 to S phase of the cell cycle (10,11). Therefore,
we investigated whether FHL2 inhibits cell proliferation
and opposes Id2-mediated entry into the S phase.
FHL2 transfection markedly inhibited the colony forma-
tion of both SK–N–SH and SH–SY5Y cells, whereas Id2
or Id2-del transfection promoted colony formation
(Figure 6A). These results clearly demonstrate the oppo-
site eﬀect of FHL2 and Id2 on cell proliferation. Next,
SK–N–SH and SH–SY5Y cells were cotransfected with
FHL2 and Id2 in the presence of a GFP expression plas-
mid, and the rate of DNA synthesis was measured by
incorporation of BrdU in GFP-positive cells. As shown
in Figure 6B, ectopic FHL2 strongly inhibited S phase
entry and abrogated Id2-stimulated DNA synthesis. To
conﬁrm whether this eﬀect resulted from the direct inter-
action of FHL2 and Id2, we transiently transfected Id2-del
or Id2-del plus FHL2 into SH–SY5Y cells and performed
BrdU incorporation assays (Figure 6C). Although the sig-
niﬁcant promotion of S phase entry was observed in both
Id2-del and wild-type Id2 cells, the promotional eﬀect in
Id2-del cells was not abolished by FHL2 as for wild-type
Id2. Next, we performed BrdU incorporation assays
in FHL2-siRNA-transfected SH–SY5Y cells. Not unex-
pectedly, transfection of FHL2-speciﬁc siRNA slightly
but not signiﬁcantly promoted the S-phase entry because
of the very weak and even negligible expression level of
FHL2 in SH–SY5Y cells (Figure 6D). Similarly,
FHL2-siRNA transduction did not signiﬁcantly promote
the S-phase entry of SK–N–SH cells (data not shown).
Altogether, these data suggest that the ectopic or
RA-induced expression of FHL2 can eﬀectively inhibit
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Nucleic Acids Research, 2009,Vol.37, No. 12 4005cell-cycle progression of neuroblastoma cells by antago-
nizing Id2 activity.
FHL2 up-regulates the expression of E47 target genes
by inactivating Id2 activity in SK–N–SH cells
To test whether FHL2 aﬀects the expression of E47–Id2
transcriptome targets, we chose p57
Kip2, IGF2 and H19
genes to measure their mRNA expression by performing
qPCR. As shown in Figure 7A, FHL2 transfection mark-
edly up-regulated the mRNA expression of p57
Kip2, IGF2
and H19. Ectopic FHL2 expression did not change the
protein levels of Id2, E47and b-actin but increased the
protein level of p57
Kip2. To check whether the up-regula-
tion of E47 target genes induced by FHL2 was a conse-
quence of the functional regulation of the E47–Id2
transcriptome by FHL2, we measured the protein
level of p57
Kip2 in E47, Id2 and/or FHL2-transfected
SK–N–SH cells (Figure 7B). Similar to a previous report
(27), E47 eﬀectively induced the accumulation of p57
Kip2
in cells, and this eﬀect was abolished by Id2. Ectopic
expression of FHL2 reversed the repressive eﬀect of Id2
and partially restored E47-induced p57
Kip2 up-regulation.
Finally, to further validate whether the induction of E47
target genes by FHL2 is directly linked to the FHL2–Id2
association, we performed qPCR for p57
Kip2 in SK–N–SH
cells (Figure 7C). Id2 induced a signiﬁcant decrease of
p57
Kip2 mRNA expression, but this eﬀect was markedly
attenuated by FHL2. Similar to wild-type Id2, Id2-del
also induced a similar decrease of p57
Kip2 mRNA expres-
sion; however, this eﬀect was not abrogated by FHL2.
Taken together, these data indicate that FHL2 is able to
eﬀectively up-regulate the expression of E47 target genes
in neuroblastoma cells by directly interacting with and
preventing Id2 from binding to E47.
DISCUSSION
The biological function of Id proteins is achieved through
antagonizing the activity of their associated bHLH tran-
scription factors (1,2). Although the molecular mechanism
involved in this process has been well dissected, additional
regulators should work in concert with Ids in view of
the spatio-temporal variation of Id-controlled gene
expression. In this study, the LIM-only protein FHL2, a
well-known cofactor or adaptor of several transcription
factors (19), was identiﬁed as a novel Id2 interactor. In
addition, the interaction of FHL2 with three other mem-
bers of the Id protein family (Id1, Id3 and Id4) was
demonstrated in GST-pulldown in vitro assays. We further
show that FHL2 blocks Id–E47 coupling by a competitive
binding mechanism, which subsequently represses the
inhibitory eﬀect of Ids on E47-mediated transcription.
Finally, the FHL2 regulation of the E47–Id2 transcrip-
tome was extended to the proliferation of the neuro-
blastma cells. These ﬁndings underscore an important
function of FHL2 in regulating the Id2 signaling pathway.
The LIM domain-containing proteins can function as
adaptors or scaﬀolds to support the assembly of multi-
meric protein complexes and can operate as competitors,
autoinhibitors and localizers (38,39). As a member of the
LIM protein family, FHL2 has been shown to associate
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4006 Nucleic Acids Research, 2009, Vol. 37,No. 12with several transcriptional factors or signaling transdu-
cers such as AR, CBP/p300, b-catenin, FOXO1, AP1 and
TRAF6, to regulate signal transduction and gene expres-
sion (19). In most cases, FHL2 protein appears to partic-
ipate in functional complexes to modulate the tissue-
speciﬁc activity of activators or repressors. One possible
explanation for the dual role of FHL2 in a transcription or
regulating signaling pathway might be that FHL2 acts to
stabilize the functional complexes as a type of bridging
factor. This explanation was supported by the fact, like
that the formation of a ternary complex by FHL2, CBP/
p300, and b-catenin could synergistically activate AR-
mediated transcription (28), and that FHL2 interacts
with titin, a protein that plays a crucial role as organizer
of the sarcomere, and functions as an adaptor molecule
that links the metabolic enzymes MM-creatine kinase,
adenylate cyclase and phosphofructokinase to titin,
thereby helping to recruit metabolic enzymes needed for
energy provision during muscle contraction (40). In dra-
matic contrast, we observed that FHL2 acts as a compet-
itor of E47 for Id2 binding and subsequently allows E47 to
recruit to its target DNA and execute its transcriptional
activity (Figure 3 and 4). Although diﬀerent epitopes of
Id2 are required for FHL2 and E47 binding, the binding
site for FHL2 or E47 of Id2 may be masked by a confor-
mational change of Id2 when it is occupied by FHL2 or
E47. In addition, Id2 may not provide enough surface
space to simultaneously interact with multiple proteins;
after all, Id2 is only 18kDa. Indeed, such competi-
tive binding is also observed for other FHL2-interacting
molecules. For example, the cytoplasmic domain of
TRAF6, which is formed by few amino acid numbers,
can provide a binding surface for only FHL2 or RANK.
As a consequence, FHL2 antagonizes the RANK–
TRAF6 interaction and blunts the RANK–TRAF6 sig-
naling (41).
Emerging evidence has linked FHL2 to cell-cycle
progression. However, the function of FHL2 in cell pro-
liferation is particularly intriguing, because it may exert a
positive or negative eﬀect on cell-cycle-regulated processes
in a tissue-dependent fashion. This dual nature of FHL2
can be explained by the ﬁnding that FHL2 can function as
a repressor or activator of transcriptional activity depend-
ing on the cell type. For example, FHL2 promoted SKI-
induced proliferation of UCD-Mel-N melanoma cells and
enhanced proliferation of MDA-MB-231 human breast
cancer cells by regulating cell-cycle-dependent p21 expres-
sion (42,43). Loss of FHL2 downregulated the expression
of cyclin D1 and greatly reduced the proliferative capacity
of mouse embryo ﬁbroblasts (44). In contrast, FHL2
antagonized the proliferation of diﬀerentiated myoblasts
by downregulating cyclin D1 (45) and suppressed liver
cancer cell growth through a TGF b-like pathway (24).
In this study, we demonstrated an antagonistic eﬀect of
FHL2 on Id2-driven proliferation of neuroblastoma cell
types. The p57
Kip2, IGF2 and H19 genes, belonging to the
human chromosome 11p15.5-imprinted cluster, which
have crucial functions in diﬀerentiation, the cell cycle
and oncogenesis (46–48), are within the small group of
E47–Id2 targets (27). In accordance with a previous
report (27), we also demonstrated that the expression of
these genes was strongly induced by E47 and inhibited by
Id2. Among them, p57
Kip2 is one of the three members of
the Cip/Kip family of cyclin-dependent kinase inhibitors
and a well-known cell-cycle regulator (49), the induction
of which is essential for E47-mediated inhibition of the
cell cycle in neuroblastoma cells (27). Ectopic expression
of FHL2 in neuroblastoma cells strongly induced the
expression of p57
Kip2, IGF2 and H19 genes by regulating
the Id2–E47 transcriptome (Figure 7). Given the onco-
genic activity of Id2 in tumors from the nervous system,
our data suggest that FHL2 possesses a tumor suppressor
function in these cell types.
Id family proteins were implicated in the control of
diﬀerentiation in organisms from ﬂy to human (1,6).
There is general agreement with the notion that diﬀeren-
tiation of a variety of cell types requires elimination of
the Id function. Thus, the functional inhibitors of Id
proteins might possess the potential to facilitate cell diﬀer-
entiation. Here, we demonstrated a reverse expression
relation between Id2 and its functional repressor FHL2
in diﬀerentiated neuroblastoma cells induced by RA
(Figure 5). In addition, independent evidences suggested
a diverse role of FHL2 and Id proteins during the diﬀer-
entiation process of myoblasts and osteoblasts (45,50).
These limited data implied that a reﬁned regulation
mechanism of Id function by FHL2 is required during
the processes of development and cellular diﬀerentiation.
In the past decade, numerous reports demonstrated the
aberrant accumulation of Id proteins in solid tumors and
Ids facilitating tumorigenesis by repressing cell diﬀerentia-
tion, stimulating cell proliferation and promoting tumor
neoangiogenesis (5–9). As a functional suppressor of Id2,
FHL2 is frequently deregulated, which includes being
overexpressed and down-regulated in various types of
tumors (21). The most common mechanism selected by
tumor cells to activate Id2 function is to elevate the
expression of Id2 gene. In this study, we demonstrated
that the expression of FHL2 is very weak and even negli-
gible in human neuroblastoma cells. Based on our ﬁnd-
ings, we suggest that tumor cells may target another level
in Id biology regulation. The fact that RA induced the
reverse expression of Id2 and its functional repressor
FHL2 (Figure 5) indicated that FHL2 may be an impor-
tant stalker against Id2 protein activity in neuroblastoma
cells. Loss of FHL2 will release the oncogenic activity of
Id2 and may contribute to tumor progression. Testing the
ratio of FHL2 to Id2 expression in human neuroblastoma
cells might be beneﬁcial to diﬀerentiate diﬀerent clino-
pathological stages.
In conclusion, these ﬁndings provide deﬁnite evidence
for FHL2–Id2 interaction and its corresponding func-
tional eﬀect. The functional activity of FHL2 acting as an
repressor of the oncogenic activity of Id2 in neuroblas-
toma cells suggests that loss of FHL2 may be involved
in tumorigenesis and progression of the nervous system.
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